Amitriptyline

Mechanism of action: Amitriptyline is a non-selective re-uptake inhibitor of norepinephrine and serotonin. It also displays cross-reactivity with opioid, cholinergic and adrenergic receptors. 

Presentation: tablet, oral solution

Suggested initial dose: 10mg at night for adults over 50kg up to a usual maximum of 75mg. The dose for neuropathic pain is lower than the anti-depressant dose.  Amitriptyline is particularly dangerous in overdose. 

It usually takes 3-7 days for the analgesic effect to become clinically beneficial. 

Oral absorption: Bioavailability of 33-62% due to first pass metabolism

Protein binding:  96% bound to plasma proteins

Metabolism: Amitriptyline undergoes hepatic oxidative metabolism by cytochrome P450s, with CYP2D6 producing inactive metabolites. CYP2C19 and CYP3A4 are responsible for the demethylation of amitriptyline to the very active metabolite, nortriptyline.

Elimination: mostly excreted in the urine as metabolites and conjugates.  Small amounts are excreted in the faeces.

Half-life: 10-28 hours for amitriptyline, and 16-30 hours for nortriptyline

Common side effects include: sedation, dry mouth, blurred vision, weight gain, urinary retention

Important cautions include: cardiac disease, glaucoma, suicide risk, seizure disorder and concomitant use of tramadol, due to the risk of serotonin syndrome. 

 

Further prescribing information (side effects, contraindications, interactions):

BNF-Amitriptyline

References

Thorn CF. Amitriptyline and Nortriptyline Pathway, Pharmacokinetics https://www.pharmgkb.org/pathway/PA166163647

Wen B, Ma L, Zhu M.  Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline.  Chemico-Biological Interactions 2008; 173(1): 59-67